How Health Policies May Take Shape in a Post-Humira-Exclusive Adalimumab Market
Season 5, Episode 2, Jul 24, 2022, 11:00 AM
On this podcast episode, The Center for Biosimilars spoke with Chronic Manolis from UPMC Health Plan to discuss how health care policies may shift as adalimumab biosimilars referencing Humira come to market in 2023, including how providers and payers can ensure equitable access.
To learn more about the hype regarding adalimumab biosimilars in the US, click here.
To see which biosimilars have been approved by the FDA, click here.
To read more on PBMs and their influence on biosimilar uptake, click here.
To read Manolis’ 2016 paper, click here.